Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer

Abstract

We provide best available evidence to guide treatment when atypical <i>RAS</i> variants are identified. <i>KRAS</i> L19F, Q22K, D33E, and T50I are more prevalent than many guideline-included <i>RAS</i> variants and functionally relevant.